BioCryst Pharmaceuticals, Inc. (BCRX), on Tuesday announced it has entered into a definitive agreement to acquire Astria Therapeutics, Inc. (ATXS), a biopharmaceutical company, for cash and stock valued at approximately $13.00 per Astria share, representing an enterprise value of about $700 million.
The transaction is expected to close in the first quarter of 2026.
Under the agreement, Astria shareholders will receive $8.55 in cash and 0.59 BioCryst shares per Astria share, implying a 53% premium to Astria's October 13 closing price and 71% over its 20-day VWAP.
The company will fund the cash portion through existing cash and a new $550 million debt facility from Blackstone, following the repayment of its remaining Pharmakon debt after selling its European business earlier this month.
The company will also acquire Astria's early-stage atopic dermatitis program, STAR-0310, and plans to explore strategic alternatives for the asset.
Astria shareholders will own about 15% of the combined company upon completion.
Upon completion, Astria CEO Jill Milne will join the company board of directors.
The company expected the transaction to enhance long-term revenue growth, maintain near-term profitability, and generate operating synergies after the anticipated launch of navenibart.
In the pre-market trading, BioCryst Pharmaceuticals is 16.19% lesser at $5.90 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.